CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...
Phase 2
San Antonio, Texas, United States and 66 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
San Antonio, Texas, United States and 202 other locations
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...
Phase 3
San Antonio, Texas, United States and 244 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
San Antonio, Texas, United States and 242 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
San Antonio, Texas, United States and 82 other locations
standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an eq...
Phase 3
San Antonio, Texas, United States and 50 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
San Antonio, Texas, United States of America and 73 other locations
(ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escal...
Phase 1
San Antonio, Texas, United States and 11 other locations
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advance...
Phase 3
San Antonio, Texas, United States and 229 other locations
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors....
Phase 1
San Antonio, Texas, United States and 50 other locations
Clinical trials
Research sites
Resources
Legal